Comparison of Her-2, EGFR and Cyclin D1 in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical and Chromogenic In Situ Hybridization Study

다국어 초록 (Multilingual Abstract)

The significant advance in the development of molecular-targeting drugs has made

an evaluation of Her-2, EGFR, and cyclin D1 an important clinical issue in breast

cancer patients. This study compared the Her-2, EGFR, and cyclin D1 status of

primary tumors as well as their matching lymph node metastases using immunohistochemistry

(IHC) and chromogenic in situ hybridization (CISH) in 73 breast

cancer patients. Her-2, EGFR, and cyclin D1 protein showed a concordance between

the primary lesion and the metastatic regional lymph nodes in 82%, 90%,

and 63%, respectively. CISH also revealed 92%, 93%, and 85% concordance in

the gene amplification status of Her-2, EGFR, and cyclin D1, showing a reasonable

agreement between primary tumors and metastatic regional lymph nodes.

Although a statistically significant agreement was found in Her-2 expression, a relatively

high discordance rate (18%) raises a little concern. Our findings suggest

that the Her-2 status can be reliably assessed on primary tumor but a possible difference

can be found in Her-2, EGFR, and cyclin D1 status between the primary

and the metastatic sites and this possibility should be concerned in patients considering

molecular targeted therapy or patients with progress of disease.

참고문헌 (Reference)

1 Edgerton SM, "erbB-2 (HER-2) and breast cancer progression" 11 : 214-221, 2003

2 Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2" 344 : 783-792, 2001

3 Landis JR, "The measurement of observer agreement for categorical data" 33 : 159-174, 1977

4 Foster RS Jr, "The biologic and clinical significance of lymphatic metastases in breast cancer" 5 : 79-104, 1996

5 Ross JS, "The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy" 16 : 413-428, 1998

6 Yu Q, "Specific protection against breast cancers by cyclin D1 ablation" 411 : 1017-1021, 2001

7 Hwang TS, "Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients" 53 : 74-80, 2003

8 Allred DC, "Prognostic and predictive factors in breast cancer by immunohistochemical analysis" 11 : 155-168, 1998

9 Simon R, "Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer" 1141-1146, 2001

10 Agrawal A, "Overview of tyrosine kinase inhibitors in clinical breast cancer" 12 : 135-144, 2005

11 Lacroix H, "Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases" 4 : 145-151, 1989

12 Cobleigh MA, "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease" 17 : 2639-2648, 1999

13 Davidoff AM, "Maintenance of p53 alterations throughout breast cancer progression" 51 : 2605-2610, 1991

14 Iglehart JD, "Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer" 34 : 253-263, 1995

15 Carlsson J, "HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review" 90 : 2344-2348, 2004

16 Bhargava R, "Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma" 13 : 213-216, 2004

17 Naidu R, "Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters" 9 : 409-416, 2002

18 Cardoso F, "Evaluation of HER2, p53, bcl- 2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes" 12 : 615-620, 2001

19 Tsutsui S, "EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer" 28 : 383-387, 2002

20 Bhargava R, "EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations" 18 : 1027-1033, 2005

21 Hao X, "Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis" 100 : 1110-1122, 2004

22 Arnold A, "Cyclin D1 in breast cancer pathogenesis" 23 : 4215-4224, 2005

23 Zhu XL, "Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma" 11 : 1082-1088, 1998

24 Roy PG, "Cyclin D1 and breast cancer" 15 : 718-727, 2006

25 Italiano A, "Comparison of the epidermal growth factor receptor gene and protein in primary non-small-celllung cancer and metastatic sites: implications for treatment with EGFR-inhibitors" 17 : 981-985, 2006

26 Gupta D, "Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer" 119 : 381-387, 2003

27 Gong Y, "Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma" 103 : 1763-1769, 2005

28 Gancberg D, "Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites" 13 : 1036-1043, 2002

29 Chung KY, "Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry" 23 : 1803-1810, 2005

30 Fidler IJ, "Biological diversity in metastatic neoplasms: origins and implications" 217 : 998-1003, 1982

31 Masood S, "Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study" 30 : 259-265, 2000

32 Thor A, "Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response?" 93 : 1120-1121, 2001

33 Tanner M, "Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer" 61 : 5345-5348, 2001

34 Gillett C, "Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining" 54 : 1812-1817, 1994

35 Jirstrom K, "Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification" 65 : 8009-8016, 2005